GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annexon Inc (NAS:ANNX) » Definitions » PB Ratio

ANNX (Annexon) PB Ratio : 1.44 (As of Dec. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Annexon PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-12-12), Annexon's share price is $4.51. Annexon's Book Value per Share for the quarter that ended in Sep. 2024 was $3.14. Hence, Annexon's PB Ratio of today is 1.44.

The historical rank and industry rank for Annexon's PB Ratio or its related term are showing as below:

ANNX' s PB Ratio Range Over the Past 10 Years
Min: 0   Med: 0   Max: 3.03
Current: 1.44

During the past 6 years, Annexon's highest PB Ratio was 3.03. The lowest was 0.00. And the median was 0.00.

ANNX's PB Ratio is ranked better than
69.59% of 1279 companies
in the Biotechnology industry
Industry Median: 2.52 vs ANNX: 1.44

During the past 12 months, Annexon's average Book Value Per Share Growth Rate was 6.50% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -29.20% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Annexon was -29.20% per year. The lowest was -29.20% per year. And the median was -29.20% per year.

Back to Basics: PB Ratio


Annexon PB Ratio Historical Data

The historical data trend for Annexon's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annexon PB Ratio Chart

Annexon Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - 2.77 1.91 1.07 1.42

Annexon Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.80 1.42 2.47 1.43 1.89

Competitive Comparison of Annexon's PB Ratio

For the Biotechnology subindustry, Annexon's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Annexon's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Annexon's PB Ratio distribution charts can be found below:

* The bar in red indicates where Annexon's PB Ratio falls into.



Annexon PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Annexon's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Sep. 2024)
=4.51/3.137
=1.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Annexon  (NAS:ANNX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Annexon PB Ratio Related Terms

Thank you for viewing the detailed overview of Annexon's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Annexon Business Description

Traded in Other Exchanges
N/A
Address
1400 Sierra Point Parkway, Suite 200, Building C, Brisbane, CA, USA, 94005
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Executives
William H. Carson director C/O PREVAIL THERAPEUTICS INC., 430 EAST 29TH STREET, SUITE 1520, NEW YORK NY 10016
Ted Yednock officer: EVP & Chief Innovation Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Jennifer Lew officer: EVP & Chief Financial Officer 2929 SEVENTH STREET, SUITE 100, BERKELEY CA 94710
Michael Overdorf officer: EVP & Chief Business Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Douglas Love director, officer: President & CEO C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Muneer A Satter director C/O SATTER INVESTMENT MANAGEMENT, LLC, 676 NORTH MICHIGAN AVENUE, SUITE 4000, CHICAGO IL 60611
Jamie Dananberg officer: Chief Medical Officer 3280 BAYSHORE BOULEVARD, BRISBANE CA 94005
Bain Capital Life Sciences Fund, L.p. 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116
Dean Richard Artis officer: EVP & Chief Scientific Officer C/O ANNEXON, INC., 1400 SIERRA PT PKWY, BLDG C, 2ND FLOOR, BRISBANE CA 94005
Bettina M. Cockroft director C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Larry Mattheakis officer: Chief Scientific Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
William D. Waddill director C/O CALITHERA BIOSCIENCES, 343 OYSTER POINT BLVD, SUITE 200, SO. SAN FRANCISCO CA 94080
Sanjay Keswani officer: EVP & Chief Medical Officer C/O ANNEXON, INC., 180 KIMBALL WAY, SUITE 200, SOUTH SAN FRANCISCO CA 94080
Clarus Lifesciences Iii, L.p. 10 percent owner 101 MAIN STREET, SUITE 1210, CAMBRIDGE MA 02142
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

Annexon Headlines

From GuruFocus